0
Skip to Content
CYTIMMUNE SCIENCES
About
Technology
Pipeline
Partnering
Investors
Media
Contact
CYTIMMUNE SCIENCES
About
Technology
Pipeline
Partnering
Investors
Media
Contact
About
Technology
Pipeline
Partnering
Investors
Media
Contact

Cytimmune Sciences

Cytimmune Sciences, Inc., is a privately held company incorporated in Delaware, USA.

Copyright 2021

About Us

Cytimmune’s labs are in Rockville, Maryland. Our leadership team is based in both Rockville and Boston, Massachusetts. We are a biotechnology company with a focus on clinical development of novel therapies that meet unmet medical needs.

More About Us

Get In Touch

15010 Broschart Road, Suite 180, Rockville, MD 20850

Direction and Maps

Contact Us

Inquire about Job Openings

Social Channels

Follow us on Twitter

Connect on LinkedIn

NOTICE

No IO+ therapeutic including CYT-6091 has been approved for clinical use. Cytimmune does not currently have any ongoing clinical trial that would enable a patient in the United States, Europe, or elsewhere to receive CYT-6091 or any other IO+ therapeutic. Unless otherwise stated, claims on this website with regard to mechanism of action, safety, and efficacy are based on studies conducted primarily in small animal models of cancer. CYT-6091 is the only Cytimmune therapy that has been studied in a human clinical trial. A summary of that study is available here.